No Data
No Data
雲康集團:2023年度報告
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
YUNKANG GROUP(2325.HK):BACK TO NORMAL GROWTH
Yunkang Group reported 2023 revenue of RMB891.5mn, down by 76.3% YoY, primarily
Yunkang Group has received “buy” ratings from many major banks, which is optimistic about the long-term development trend of the industry
Gelonghui, April 9 | Yunkang Group recently received “buy” ratings from major banks such as CMB International and SPDB International. CMB International released a research report to maintain Yunkang Group (2325.HK)'s “buy” rating. The target price is HK$13.78. The research report mentioned that Yunkang Group's revenue in 2023 was RMB 890 million, and the non-COVID-19 business increased 26.9% year over year. Therefore, the bank believes that revenue will return to normal growth in 2024E, driven by the steady performance of core businesses such as pathological diagnosis, infectious disease testing, genetic disease diagnosis, and routine testing. As of December 31, 2023, Yunkangji
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Read Yunkang Group (2325.HK)'s 2023 performance report in one picture
On March 25, Yunkang Group (2325.HK) announced its 2023 results announcement. In 2023, the company recorded revenue of 892 million yuan (RMB, same unit), an increase of 31.5% compared with 2019. As of December 31, 2023, Yunkang's customers spread across 31 provinces and autonomous regions, and more than 200 cities. It has built 416 medical consortium on-site diagnosis centers, 1,500+ medical and non-medical institutions, 3,900 medical and non-medical institutions, with more than 3,000 testing projects, and the company has more than 800 doctors and medical technicians. underneath
No Data